What is claimed is:

1. Use of a therapeutically effective amount of an antibody or antigen-binding fragment thereof that specifically binds programmed death 1 (PD-1) in the manufacture of a medicament for treating or inhibiting the growth of a MUC16-expressing tumor in a subject in combination with a therapeutically effective amount of a bispecific antibody comprising a first antigen-binding arm that specifically binds MUC16 and a second antigen-binding arm that specifically binds CD3, wherein:

(a) the antibody or antigen-binding fragment thereof that specifically binds PD-1 comprises three heavy chain complementarity determining regions, HCDR1, HCDR2, HCDR3, and three light chain complementarity determining regions, LCDR1, LCDR2, and LCDR3, wherein HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 comprise the amino acid sequences of SEQ ID NOs: 35, 36, 37, 38, 39, and 40, respectively;

(b) the first antigen-binding arm of the bispecific antibody comprises three heavy chain complementarity determining regions, A-HCDR1, A-HCDR2 and A-HCDR3, and three light chain complementarity determining regions, A-LCDR1, A-LCDR2 and A-LCDR3, wherein A-HCDR1, A-HCDR2, A-HCDR3, A-LCDR1, A-LCDR2, and A-LCDR3 comprise the amino acid sequences of SEQ ID NOs: 8, 9, 10, 11, 12 and 13, respectively; and

(c) the second antigen-binding arm of the bispecific antibody comprises three heavy chain complementarity determining regions, B-HCDR1, B-HCDR2 and B-HCDR3, and three light chain complementarity determining regions, B-LCDR1, B-LCDR2 and B-LCDR3, wherein B-HCDR1, B-HCDR2, B-HCDR3, B-LCDR1, B-LCDR2, and B-LCDR3 comprise the amino acid sequences of SEQ ID NOs: 14, 15, 16, 11, 12, and 13, respectively, or SEQ ID NOs: 26, 27, 28, 11, 12, and 13, respectively.

2. Use of a therapeutically effective amount of a bispecific antibody comprising a first antigen-binding arm that specifically binds MUC16 and a second antigen-binding arm that specifically binds CD3 in the manufacture of a medicament for treating or inhibiting the growth of a MUC16-expressing tumor in a subject in combination with a therapeutically effective amount of an antibody or antigen-binding fragment thereof that specifically binds programmed death 1 (PD-1), wherein:

(a) the antibody or antigen-binding fragment thereof that specifically binds PD-1 comprises three heavy chain complementarity determining regions, HCDR1, HCDR2, HCDR3, and three light chain complementarity determining regions, LCDR1, LCDR2, and LCDR3,

wherein HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 comprise the amino acid sequences of SEQ ID NOs: 35, 36, 37, 38, 39, and 40, respectively;

(b) the first antigen-binding arm of the bispecific antibody comprises three heavy chain complementarity determining regions, A-HCDR1, A-HCDR2 and A-HCDR3, and three light chain complementarity determining regions, A-LCDR1, A-LCDR2 and A-LCDR3, wherein A-HCDR1, A-HCDR2, A-HCDR3, A-LCDR1, A-LCDR2, and A-LCDR3 comprise the amino acid sequences of SEQ ID NOs: 8, 9, 10, 11, 12 and 13, respectively; and

(c) the second antigen-binding arm of the bispecific antibody comprises three heavy chain complementarity determining regions, B-HCDR1, B-HCDR2 and B-HCDR3, and three light chain complementarity determining regions, B-LCDR1, B-LCDR2 and B-LCDR3, wherein B-HCDR1, B-HCDR2, B-HCDR3, B-LCDR1, B-LCDR2, and B-LCDR3 comprise the amino acid sequences of SEQ ID NOs: 14, 15, 16, 11, 12, and 13, respectively, or SEQ ID NOs: 26, 27, 28, 11, 12, and 13, respectively.

3. The use according to claim 1 or 2 , wherein:

(a) the antibody or antigen-binding fragment that specifically binds PD-1 is to be administered to the subject prior to, concurrent with or after the bispecific antibody;

(b) the antibody or antigen-binding fragment that specifically binds PD-1 is to be administered to the subject prior to the bispecific antibody; or

(c) one or more doses of the antibody or antigen-binding fragment that specifically binds PD-1 is to be administered to the subject in combination with one or more doses of the bispecific antibody.

4. The use according to claim 3, wherein the antibody or antigen-binding fragment that specifically binds PD-1 is to be administered to the subject at least 1 week prior to the bispecific antibody.

5. The use according to any one of claims 1-4, wherein:

(a) the antibody or antigen-binding fragment that specifically binds PD-1 is to be administered at a dose of between 0.1 mg/kg and 20 mg/kg of the subject's body weight;

(b) the bispecific antibody is to be administered at a dose of between 0.1 mg/kg and 20 mg/kg of the subject's body weight;

(c) each dose of the antibody or antigen-binding fragment that specifically binds PD-1 is to be administered 0.5-12 weeks after the immediately preceding dose;

(d) each dose of the bispecific antibody is to be administered 0.5-12 weeks after the immediately preceding dose; and/or

(e) the antibodies are to be administered intravenously, subcutaneously, or intraperitoneally.

6. The use according to claim 5, wherein each dose of the antibody or antigen-binding fragment that specifically binds PD-1 comprises 10 to 8000 micrograms.

7. The use according to claim 5 or 6, wherein each dose of the bispecific antibody comprises 10 to 8000 micrograms.

8. The use according to any one of claims 1-7, wherein:

(a) the tumor comprises an ovarian cancer or the tumor comprises a pancreatic cancer; and/or

(b) the subject is resistant or inadequately responsive to, or relapsed after, prior therapy.

9. The use according to any one of claims 1-8, wherein the combination is to be administered to the subject with a third therapeutic agent or therapy.

10. The use according to claim 9, wherein the third therapeutic agent or therapy is selected from the group consisting of radiation, surgery, a chemotherapeutic agent, a cancer vaccine, a PD-L1 inhibitor, a LAG-3 inhibitor, a CTLA-4 inhibitor, a TIM3 inhibitor, a BTLA inhibitor, a TIGIT inhibitor, a CD47 inhibitor, an indoleamine-2,3-dioxygenase (IDO) inhibitor, a vascular endothelial growth factor (VEGF) antagonist, an angiopoietin-2 (Ang2) inhibitor, a transforming growth factor beta (TGF.beta.) inhibitor, an epidermal growth factor receptor (EGFR) inhibitor, an antibody to a tumor-specific antigen, Bacillus Calmette-Guerin vaccine, granulocyte-macrophage colony-stimulating factor, a cytotoxin, an interleukin 6 receptor (IL-6R) inhibitor, an interleukin 4 receptor (IL-4R) inhibitor, an IL-10 inhibitor, IL-2, IL-7, IL-21, IL-15, an antibody-drug conjugate, an anti-inflammatory drug, and a dietary supplement.

11. The use according to any one of claims 1-10, wherein the first antigen-binding arm of the bispecific antibody comprises a HCVR comprising the amino acid sequence of SEQ ID NO: 1, and a LCVR comprising the amino acid sequence of SEQ ID NO: 2.

12. The use according to any one of claims 1-11, wherein B-HCDR1, B-HCDR2, B-HCDR3, B-LCDR1, B-LCDR2, and B-LCDR3 of the second antigen-binding arm of the

bispecific antibody comprise the amino acid sequences of SEQ ID NOs: 14, 15, 16, 11, 12, and 13, respectively.

13. The use according to claim 12, wherein the second antigen-binding arm of the bispecific antibody comprises a heavy chain variable region (HCVR) comprising the amino acid sequence of SEQ ID NO: 3, and a light chain variable region (LCVR) comprising the amino acid sequence of SEQ ID NO: 2.

14. The use according to any one of claims 1-11, wherein B-HCDR1, B-HCDR2, B-HCDR3, B-LCDR1, B-LCDR2, and B-LCDR3 of the second antigen-binding arm of the bispecific antibody comprise the amino acid sequences of SEQ ID NOs: 26, 27, 28, 11, 12, and 13, respectively.

15. The use according to claim 14, wherein the second antigen-binding arm of the bispecific antibody comprises a HCVR comprising the amino acid sequence of SEQ ID NO: 7, and a LCVR comprising the amino acid sequence of SEQ ID NO: 2.

16. The use according to any one of claims 1-15, wherein the antibody or antigen-binding fragment thereof that specifically binds PD-1 comprises a HCVR comprising the amino acid sequence of SEQ ID NO: 33, and a LCVR comprising the amino acid sequence of SEQ ID NO: 34.

17. The use according to any one of claims 1-13 or 16, wherein the bispecific antibody comprises a first heavy chain comprising the amino acid sequence of SEQ ID NO: 29 paired with a light chain comprising the amino acid sequence of SEQ ID NO: 30, and a second heavy chain comprising the amino acid sequence of SEQ ID NO: 31 paired with a light chain comprising the amino acid sequence of SEQ ID NO: 30.

18. The use according to any one of claims 1-11 or 14-16, wherein the bispecific antibody comprises a first heavy chain comprising the amino acid sequence of SEQ ID NO: 29 paired with a light chain comprising the amino acid sequence of SEQ ID NO: 30, and a second heavy chain comprising the amino acid sequence of SEQ ID NO: 32 paired with a light chain comprising the amino acid sequence of SEQ ID NO: 30.

19. The use according to any one of claims 1-18, wherein the antibody that specifically binds PD-1 comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 41, and a light chain comprising the amino acid sequence of SEQ ID NO: 42.